10 Best Small-Cap Healthcare Stocks To Buy Now

4. Kura Oncology, Inc. (NASDAQ:KURA)

Number of Hedge Fund Holders: 33 

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s primary focus is on developing small-molecule inhibitors that target specific genetic and epigenetic abnormalities in cancer cells.

One of the primary growth catalysts for Kura Oncology, Inc. (NASDAQ:KURA) is its focus on developing targeted cancer therapies, particularly its lead product candidate, ziftomenib, which is in clinical trials for the treatment of NPM1-mutant acute myeloid leukemia (AML). The company has reported successful enrollment in its KOMET-001 trial and is progressing with the KOMET-007 combination trial. Additionally, Kura Oncology recently completed a $150 million private placement, which is expected to fund its operations into 2027. This financial boost will support ongoing research and development efforts, potentially accelerating the path to market for its therapies.

Troy Wilson, the Co-Founder of Kura Oncology, Inc. (NASDAQ:KURA), stated the following about Ziftomenib in the Q2 2024 earnings call transcript:

“I’m pleased to report that the safety, tolerability, and clinical activity of ziftomenib continue to support advancement into both the FIT and UNFIT frontline populations. Two of the four cohorts have cleared the 600-milligram dose and advanced into the Phase 1b expansion study. The two remaining cohorts are expected to clear the 600-milligram dose and advance shortly. The Phase 1b expansion study includes multiple combination cohorts, most notably ziftomenib plus Ven/Aza, in newly diagnosed NPM1-mutant or KMT2A-rearranged AML, as well as ziftomenib plus 7+3 in newly diagnosed NPM1-mutant or KMT2A-rearranged AML, removing the requirement for patients to have high-risk disease. Each combination cohort is enrolling independently, and we expect to enroll approximately 20 patients per cohort.”

As of Q2 2024, around 33 hedge fund holders held stakes in the stock with Suvretta Capital Management being the largest stakeholder with 7,069,627 shares worth $145,563,620. The stock has a Strong Buy rating based on 10 Wall Street Analysts. The average price target is $30.89, with forecasts ranging from $22.00 to $37.00, indicating a 46.68% increase from the current price of $21.06.